SELL and neoplasm: However, when B/I activated lymphocyte subsets were used to treat slightly larger tumors (inoculated at 100,000 cells/mouse, 2x the usual inoculum), CD62L- →CD62L+ cells were not effective at mediating tumor regression, slowing tumor growth only slightly (Figure 5b).